粘膜炎
势垒函数
封堵器
下调和上调
肠粘膜
TLR2型
炎症
TLR4型
癌症研究
紧密连接
医学
免疫学
生物
内科学
化疗
细胞生物学
基因
生物化学
作者
Fernanda Alvarenga Lima Barroso,Luís Cláudio Lima de Jesus,Tales Fernando da Silva,Viviane Lima Batista,Juliana Guimarães Laguna,Nina Dias Coelho-Rocha,Kátia Duarte Vital,Simone Odília Antunes Fernandes,Valbert Nascimento Cardoso,Ênio Ferreira,Flaviano S. Martins,Mariana Martins Drumond,Pamela Mancha-Agresti,Alexander Birbrair,Debmalya Barh,Vasco Azevedo
标识
DOI:10.3389/fmicb.2022.858036
摘要
Intestinal mucositis promoted by the use of anticancer drugs is characterized by ulcerative inflammation of the intestinal mucosa, a debilitating side effect in cancer patients undergoing treatment. Probiotics are a potential therapeutic option to alleviate intestinal mucositis due to their effects on epithelial barrier integrity and anti-inflammatory modulation. This study investigated the health-promoting impact of Lactobacillus delbrueckii CIDCA 133 in modulating inflammatory and epithelial barrier markers to protect the intestinal mucosa from 5-fluorouracil-induced epithelial damage. L. delbrueckii CIDCA 133 consumption ameliorated small intestine shortening, inflammatory cell infiltration, intestinal permeability, villus atrophy, and goblet cell count, improving the intestinal mucosa architecture and its function in treated mice. Upregulation of Muc2, Cldn1, Hp, F11r, and Il10, and downregulation of markers involved in NF-κB signaling pathway activation (Tlr2, Tlr4, Nfkb1, Il6, and Il1b) were observed at the mRNA level. This work suggests a beneficial role of L. delbrueckii strain CIDCA 133 on intestinal damage induced by 5-FU chemotherapy through modulation of inflammatory pathways and improvement of epithelial barrier function.
科研通智能强力驱动
Strongly Powered by AbleSci AI